EDIT-401
Hyperlipidemia & Atherosclerotic Cardiovascular Disease (ASCVD)
PreclinicalActive
Key Facts
Indication
Hyperlipidemia & Atherosclerotic Cardiovascular Disease (ASCVD)
Phase
Preclinical
Status
Active
Company
About Editas Medicine
Editas Medicine is a clinical-stage leader in CRISPR-based gene editing, founded in 2013 and headquartered in Cambridge, Massachusetts. The company's strategy centers on developing in vivo gene editing medicines, with its most advanced program, EDIT-401 for hyperlipidemia, poised for human proof-of-concept by end of 2026. While facing a competitive landscape and significant clinical and financial risks, Editas possesses foundational IP and a differentiated platform that could yield best-in-class, potentially curative therapies.
View full company profile